TAKEDA-PHARMACEUTICAL
27.1.2021 11:02:10 CET | Business Wire | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it achieved carbon neutrality in its value chain for its fiscal year 2019. This achievement was delivered by a continued focus on internal energy conservation measures, procurement of green energy, and investment in renewable energy certificates and high-quality, verified carbon offsets. These actions collectively address 100 percent of Takeda’s fiscal year 2019 scope 1, 2, and 3 emissions1 and represent a significant milestone in Takeda’s sustainability journey.
“This important milestone underscores our commitment to environmental sustainability as we recognize that climate change poses a risk to human health, including the spread of some of the same infectious diseases we’re working to eradicate,” said Christophe Weber, Takeda president and chief executive officer. “As a global, purpose-driven company celebrating our 240-year anniversary this summer, I am proud of our achievement, but we know much more work needs to be done. We remain committed to using our size and scale to help mitigate climate change and to ensure we can continue to make a positive impact on patients, our people and the planet.”
One of the ways Takeda achieved this milestone is through its investment in more than 30 renewable energy and carbon offset projects across 12 countries. These projects support the use of wind and solar energy, clean water availability, forest conservation and the preservation of biodiversity. The activities collectively address 15 out of 17 of the United Nations’ Sustainable Development Goals. They support local communities, while promoting a more sustainable future. All carbon offsets were required to meet rigorous evaluation criteria, including additionality, measurability, transparency, registration and third-party verification, among others.
Projects supported include:
- Clean drinking water in Malawi – providing safe drinking water to communities by creating new boreholes and repairing damaged ones, resulting in the reduced use of firewood for boiling and purifying water
- Working Woodlands Program – preserving more than 8,600 acres in the northeastern corner of Tennessee, U.S., as a privately held park, encouraging recreation-based tourism in a lower-income region of the United States
- Forest management in Japan – supporting natural carbon sinks and local air quality through sustainable forestry management practices in Japan
- Solar cookstoves in China – helping to improve indoor air quality by investing in the installation of solar cookers to replace coal for cooking and hot water needs for rural farmers in remote areas of China
- Solar energy in India – supporting the development of solar lighting and thermal water heating to replace fossil fuel usage throughout different states in India
Building on today’s milestone, Takeda remains committed to eliminating greenhouse gas emissions from its company-wide operations. Specifically, Takeda aims to reduce 40 percent of its emissions from its operations by 2025 and has committed to being carbon zero by 2040. To achieve its climate-related goals, a company-wide, cross-divisional program has been established to increase renewable energy usage and drive energy efficiency. Takeda is also looking beyond its own operations and is working with suppliers to help them to establish science-based reduction targets and reduce greenhouse gas emissions.
As a science-driven organization, Takeda’s climate change commitments are aligned with current climate science. In 2020, the Science-Based Targets initiative (SBTi) recognized Takeda’s goals as being consistent with reductions required to limit the rise in global temperature to 1.5°C above pre-industrial levels. Takeda is also proud to have earned a spot on CDP’s ‘A List’ for climate change leadership in 2020 as well as being named to Corporate Knights Global 100 Most Sustainable Corporations in the World (Global 100) for the sixth consecutive year.
For more information on Takeda’s commitment to environmental sustainability, visit:
Takeda environment website
Sustainability Value Report 2020
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK ) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in healthcare in approximately 80 countries. For more information, visit https://www.takeda.com .
1
Scope 1 emissions are direct emissions from owned or controlled sources such as onsite fuel combustion, company-owned vehicles, and in-equipment in our facilities.
Scope 2 emissions are indirect greenhouse gas emissions resulting from purchased and consumed electricity, third party steam and/or chilled water supplied to our facilities.
Scope 3 emissions are all other indirect emissions that occur in our value chain, including goods and services provided by suppliers, business travel, employee commuting, and landfill waste disposal.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210127005034/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
